成人治疗相关B细胞急性淋巴细胞白血病具有独特的基因特征，常伴有TP53缺失且预后较差。 - Suppr

Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.

作者信息

Barnea Slonim Liron, Gao Juehua, Burkart Madelyn, Odetola Oluwatobi E, Kocherginsky Masha, Dinner Shira N, Lu Xinyan, Wehbe Firas, Jennings Lawrence, Altman Jessica K, Mirza Kamran M, Chen Yi-Hua, Sukhanova Madina

机构信息

Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Department of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

出版信息

Leukemia. 2021 Jul;35(7):2097-2101. doi: 10.1038/s41375-020-01061-9. Epub 2020 Oct 21.

DOI:10.1038/s41375-020-01061-9

PMID:33087830

Abstract

摘要

相似文献

Leukemia. 2021 Jul;35(7):2097-2101. doi: 10.1038/s41375-020-01061-9. Epub 2020 Oct 21.

TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.

Haematologica. 2013 May;98(5):e59-61. doi: 10.3324/haematol.2012.076786. Epub 2013 Feb 12.

High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.

Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11.

Impact of gene variants on prognosis and survival of childhood acute lymphoblastic leukemia.

Scand J Clin Lab Invest. 2023 May;83(3):187-193. doi: 10.1080/00365513.2023.2195682. Epub 2023 Apr 8.

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.

Haematologica. 2020 Jan;105(1):170-181. doi: 10.3324/haematol.2018.199364. Epub 2019 May 9.

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.

Blood. 2023 Mar 30;141(13):1640-1644. doi: 10.1182/blood.2022017249.

Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.

Blood Cancer Discov. 2023 Mar 1;4(2):134-149. doi: 10.1158/2643-3230.BCD-22-0154.

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.

Br J Cancer. 2017 Jul 11;117(2):256-265. doi: 10.1038/bjc.2017.152. Epub 2017 May 30.

Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.

Haematologica. 2020 Jan;105(1):10-11. doi: 10.3324/haematol.2019.234872.

Mutations in Hypodiploid Acute Lymphoblastic Leukemia.

Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a026286. doi: 10.1101/cshperspect.a026286.

引用本文的文献

Survival outcomes in secondary and primary acute lymphoblastic leukemia: a systematic review and meta-analysis.

Sci Rep. 2025 Jun 2;15(1):19282. doi: 10.1038/s41598-025-95356-5.

Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.

Bone Marrow Transplant. 2024 Mar;59(3):387-394. doi: 10.1038/s41409-023-02192-0. Epub 2024 Jan 9.

Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.

Blood Cancer Discov. 2024 May 1;5(3):164-179. doi: 10.1158/2643-3230.BCD-23-0106.

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.

Blood Adv. 2023 Jul 11;7(13):3087-3098. doi: 10.1182/bloodadvances.2022009212.

Leuk Res Rep. 2022 Nov 1;18:100358. doi: 10.1016/j.lrr.2022.100358. eCollection 2022.

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.

Blood Adv. 2023 Jan 24;7(2):236-245. doi: 10.1182/bloodadvances.2022007496.

J Cancer. 2022 Sep 11;13(12):3326-3332. doi: 10.7150/jca.76719. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.

作者信息

机构信息

Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Department of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

出版信息

Leukemia. 2021 Jul;35(7):2097-2101. doi: 10.1038/s41375-020-01061-9. Epub 2020 Oct 21.

DOI:10.1038/s41375-020-01061-9

PMID:33087830

Abstract

摘要

相似文献

Leukemia. 2021 Jul;35(7):2097-2101. doi: 10.1038/s41375-020-01061-9. Epub 2020 Oct 21.

TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.

Haematologica. 2013 May;98(5):e59-61. doi: 10.3324/haematol.2012.076786. Epub 2013 Feb 12.

High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.

Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11.

Impact of gene variants on prognosis and survival of childhood acute lymphoblastic leukemia.

Scand J Clin Lab Invest. 2023 May;83(3):187-193. doi: 10.1080/00365513.2023.2195682. Epub 2023 Apr 8.

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.

Haematologica. 2020 Jan;105(1):170-181. doi: 10.3324/haematol.2018.199364. Epub 2019 May 9.

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.

Blood. 2023 Mar 30;141(13):1640-1644. doi: 10.1182/blood.2022017249.

Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.

Blood Cancer Discov. 2023 Mar 1;4(2):134-149. doi: 10.1158/2643-3230.BCD-22-0154.

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.

Br J Cancer. 2017 Jul 11;117(2):256-265. doi: 10.1038/bjc.2017.152. Epub 2017 May 30.

Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.

Haematologica. 2020 Jan;105(1):10-11. doi: 10.3324/haematol.2019.234872.

Mutations in Hypodiploid Acute Lymphoblastic Leukemia.

Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a026286. doi: 10.1101/cshperspect.a026286.

引用本文的文献

Survival outcomes in secondary and primary acute lymphoblastic leukemia: a systematic review and meta-analysis.

Sci Rep. 2025 Jun 2;15(1):19282. doi: 10.1038/s41598-025-95356-5.

Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.

Bone Marrow Transplant. 2024 Mar;59(3):387-394. doi: 10.1038/s41409-023-02192-0. Epub 2024 Jan 9.

Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.

Blood Cancer Discov. 2024 May 1;5(3):164-179. doi: 10.1158/2643-3230.BCD-23-0106.

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.

Blood Adv. 2023 Jul 11;7(13):3087-3098. doi: 10.1182/bloodadvances.2022009212.

Leuk Res Rep. 2022 Nov 1;18:100358. doi: 10.1016/j.lrr.2022.100358. eCollection 2022.

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.

Blood Adv. 2023 Jan 24;7(2):236-245. doi: 10.1182/bloodadvances.2022007496.

J Cancer. 2022 Sep 11;13(12):3326-3332. doi: 10.7150/jca.76719. eCollection 2022.

Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.

作者信息

机构信息

出版信息

相似文献

引用本文的文献